Skip to search formSkip to main contentSkip to account menu

Avonex

National Institutes of Health

Related topics

Related topics

4 relations
Avonex PenInterferon beta-1a 0.03 MG Injection [Avonex]

Broader (2)

Interferon beta-1aInterferon-beta

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2013
2013
The Neurodegenerative Process in Multiple Sclerosis and the Possible Neuroprotective Effect of Treatment with β-Interferon 1a (Avonex)
The dynamics of changes in the N-acetylaspartate/creatine ratio (NAA/Cr) in brain tissue in patients with multiple sclerosis (MS… 
Review
2013
Review
2013
AVONEX PEN（アボネックス ペン型製剤）の有用性に関する医療従事者による評価
Background Once-a-Week-Avonex Syringe(30 μg Interferon beta-1a Intramuscular)was approved in Japan in November 2006 for the… 
2012
2012
Pulmonary administration of interferon Beta-1a-fc fusion protein in non-human primates using an immunoglobulin transport pathway.
Currently, products containing interferon beta (IFNβ) are injected either intramuscularly or subcutaneously. To avoid the… 
2012
2012
[Side-effects of the treatment with disease modifying drugs in patients with multiple sclerosis: an analysis of register data in the Yaroslavl region].
Authors have followed up 230 patients with multiple sclerosis treated with disease modifying drugs (DMD) using the data of the… 
2011
2011
Quantitative differences in the immunomodulatory effects of Rebif and Avonex in IFN-β 1a treated multiple sclerosis patients
Highly Cited
2005
Highly Cited
2005
Eight-year immunogenicity and safety of interferon beta-1a-Avonex®treatment in patients with multiple sclerosis
An open-label extension study of the phase III trial of intramuscular interferon beta-1a (IFNβ-1a-Avonex) was conducted to… 
2003
2003
[Cost-utility analisys of multiple sclerosis treatment with glatiramer acetate or interferon beta in Spain].
OBJECTIVE To carry out a cost-utility analysis of the treatment of relapsing-remitting multiple sclerosis (RRMS) with glatiramer… 
2003
2003
[Open trial of the effectiveness of interferon beta 1a (Avonex) in the treatment of multiple sclerosis in Poland: MRI results].
OBJECTIVE To assess the effect of interferon-beta 1A (IFNb 1A, Avonex) treatment on magnetic resonance (MR) image in patients… 
1999
1999
[Interferon beta-1a (Avonex TM): clinical and MRI impacts].
This article presents critical aspects of the pivotal phase III study that led to approval of interferon beta-1a (Avonex) as… 
1997
1997
Chapter 31. To Market, To Market - 1996
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)